P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 12.78 CNY -1.31% Market Closed
Market Cap: 4.4B CNY

Pulike Biological Engineering Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pulike Biological Engineering Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Pre-Tax Income
ÂĄ158m
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ5.7B
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ2.8B
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ8.5B
CAGR 3-Years
40%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ6.3B
CAGR 3-Years
28%
CAGR 5-Years
2%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
ÂĄ4B
CAGR 3-Years
N/A
CAGR 5-Years
218%
CAGR 10-Years
N/A
No Stocks Found

Pulike Biological Engineering Inc
Glance View

Market Cap
4.4B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
17.52 CNY
Undervaluation 27%
Intrinsic Value
Price
P

See Also

What is Pulike Biological Engineering Inc's Pre-Tax Income?
Pre-Tax Income
158m CNY

Based on the financial report for Sep 30, 2025, Pulike Biological Engineering Inc's Pre-Tax Income amounts to 158m CNY.

What is Pulike Biological Engineering Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
0%

Over the last year, the Pre-Tax Income growth was 40%. The average annual Pre-Tax Income growth rates for Pulike Biological Engineering Inc have been -2% over the past three years , -4% over the past five years .

Back to Top